tetano
Editor, Senior Moderator
J Transl Med
. 2020 Sep 21;18(1):359.
doi: 10.1186/s12967-020-02532-4.
The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
Maurice A Canham[SUP] 1 [/SUP], John D M Campbell[SUP] 2 [/SUP], Joanne C Mountford[SUP] 2 [/SUP]
Affiliations
Abstract
More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.
Keywords: Acute respiratory distress syndrome; COVID-19; Mesenchymal stromal cells; SARS-CoV-2
. 2020 Sep 21;18(1):359.
doi: 10.1186/s12967-020-02532-4.
The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
Maurice A Canham[SUP] 1 [/SUP], John D M Campbell[SUP] 2 [/SUP], Joanne C Mountford[SUP] 2 [/SUP]
Affiliations
- PMID: 32958009
- DOI: 10.1186/s12967-020-02532-4
Abstract
More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our lives as we battle to curtail the spread of the infection in the absence of specific therapies against coronaviruses and in anticipation of a proven safe and efficacious vaccine. Common with previous outbreaks of coronavirus infections, SARS and Middle East respiratory syndrome, COVID-19 can lead to acute respiratory distress syndrome (ARDS) that arises due to an imbalanced immune response. While several repurposed antiviral and host-response drugs are under examination as potential treatments, other novel therapeutics are also being explored to alleviate the effects on critically ill patients. The use of mesenchymal stromal cells (MSCs) for COVID-19 has become an attractive avenue down which almost 70 different clinical trial teams have ventured. Successfully trialled for the treatment of other conditions such as multiple sclerosis, osteoarthritis and graft versus host disease, MSCs possess both regenerative and immunomodulatory properties, the latter of which can be harnessed to reduce the severity and longevity of ARDS in patients under intensive care due to SARS-CoV-2 infection.
Keywords: Acute respiratory distress syndrome; COVID-19; Mesenchymal stromal cells; SARS-CoV-2